Could a weekly shot delay diabetes in cystic fibrosis? new trial launches

NCT ID NCT04731272

Recruiting now Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a weekly injection of dulaglutide, a GLP-1 drug used for diabetes, can improve early insulin release in adults with cystic fibrosis who have trouble processing sugar. About 30 participants will receive the drug or no drug in a crossover design. The goal is to see if this approach can preserve insulin-making cells and potentially delay or prevent cystic fibrosis-related diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABNORMAL GLUCOSE TOLERANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis cystic fibrosis-related diabetes diabetes mellitus exocrine pancreatic insufficiency glucose intolerance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABNORMAL GLUCOSE TOLERANCE CYSTIC FIBROSIS DIABETES PANCREATIC INSUFFICIENCY

Contacts and locations

Locations

Children's Hospital of Colorado
RECRUITING

Aurora, Colorado, 80045, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.